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SUMMARY
Protective vaccines elicit high-affinity, neutralizing
antibodies by selection of somatically hypermutated
B cell antigen receptors (BCR) on immune com-
plexes (ICs). This implicates Fc-Fc receptor (FcR)
interactions in affinity maturation, which, in turn, are
determined by IgG subclass and Fc glycan composi-
tion within ICs. Trivalent influenza virus vaccination
elicited regulation of anti-hemagglutinin (HA) IgG
subclass and Fc glycans, with abundance of sialy-
lated Fc glycans (sFc) predicting quality of vaccine
response. We show that sFcs drive BCR affinity se-
lection by binding the Type-II FcR CD23, thus upre-
gulating the inhibitory FcgRIIB on activated B cells.
This elevates the threshold requirement for BCR
signaling, resulting in B cell selection for higher affin-
ity BCR. Immunization with sFc HA ICs elicited pro-
tective, high-affinity IgGs against the conserved stalk
of the HA. These results reveal a novel, endogenous
pathway for affinity maturation that can be exploited
for eliciting high-affinity, broadly neutralizing anti-
bodies through immunization with sialylated immune
complexes.
INTRODUCTION
IC-FcR interactions mediate a wide array of cellular processes
required for maturation of protective, vaccine-induced antibody
responses, including efficient transport of antigen to the ger-
minal center, activation of T follicular helper cells, and selection
of high-affinity B cells. Indeed, FcR signaling is responsible, in
large part, for maintaining the balanced positive and negative
signaling that culminates in appropriate immune responses (Pin-
cetic et al., 2014). Two basic classes of FcRs have been identi-
fied: type I FcRs are immunoglobulin superfamily members
and include FcgRI, II, and III, while type II FcRs are C-type lectin
family members and include DC-SIGN and CD23 (Figure 1A).
Perturbations in either signaling arm result in changes in anti-
body affinity and peripheral tolerance (Bolland and Ravetch,
2000). IC-FcR interactions can initiate activating, inhibitory, or
modulatory cell signaling depending on the pattern of FcRs
engaged, which is determined by the structure of Fc domains
within an IC. Fc structure, in turn, is regulated by IgG subclass
and Fc glycan composition.
IgG antibodies exist as four subclasses in humans (IgG1-4)
with IgG1 in highest abundance in serum followed by IgG2 >
IgG3 > IgG4. This was demonstrated by the subclass distribution
of baseline (pre-vaccination) anti-HA IgGs from this study’s
cohort of ten healthy adult volunteers (Figure 1B, Figure S1).
Each subclass is distinct in its ratio of binding to activating:inhi-
bitory type 1 FcgRs, with IgG1 and IgG3 having the highest acti-
vating receptor binding affinities (Figure 1C) (Bournazos et al.,
2014; Morell et al., 1970).
The Fc glycan is an N-linked, complex, biantennary structure
attached within the Cg2 domain at Asn-297 of each IgG heavy
chain and its presence is essential for all Fc-FcR binding interac-
tions (Anthony and Ravetch, 2010). Composition of the core Fc
glycan heptasaccharide can be modified by addition of specific
saccharide units (fucose [F], N-acetylglucosamine [N], galactose
[G] and sialic acid [S]) (Figure 1D); these modifications are dy-
namic and act to regulate the biological activity of IgGmolecules
bymodulating Fc structure and, as a consequence, IC-FcR inter-
actions. At baseline, a majority of IgG Fc glycoforms are of
‘‘neutral’’ composition, defined by the presence of fucose and
absence of sialic acid (Figure 1E, neutral glycans represented
by +N and S, +F groups). sFc are present with an abundance
of5%–20% (Figure 1E, +S group) and afucosylated glycoforms
are found with an abundance of 5%–15% (Figure 1E, F
group). This distribution was demonstrated by the baseline Fc
glycoform composition on anti-HA IgG1 of this study’s patient
cohort (Figure 1E).
The most biologically significant modifications to Fc glycan
composition are sialylation and fucosylation: the presence of
sialic acid is inhibitory for type I Fc receptor binding, while the
absence of fucose enhances binding to the activating type I
FcgRIIIa. The presence of sialic acid alone is the determinant
of Fc-type II FcR binding (Figure 1F) (Anthony et al., 2008b; Son-
dermann et al., 2013). Sialylation has the effect of increasing the
conformational flexibility of the Cg2 domain, enabling the Fc to
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sample a more ‘‘closed’’ conformation (Ahmed et al., 2014)
thereby exposing binding sites for type II FcRs with correspond-
ingly reduced type I FcR binding potential. Sialylation of the Fc
glycan therefore represents a mechanism for regulating the
effector activity of immunoglobulins through alternation of Fc
conformations between open and closed states, thus regulating
Fc binding to type I or type II FcRs, respectively (Sondermann
et al., 2013). Studies on the bisecting GlcNAc modification
show possible increased type I FcgRIIIa binding affinity; how-
ever, afucosylation is a far more potent determinant of strong
FcgRIIIa binding (Hodoniczky et al., 2005; Shields et al., 2002;
Shinkawa et al., 2003; Uman˜a et al., 1999). Addition of galactose
alone to one or both arms of the branched Fc glycan does not
affect FcR binding but is significant because galactosylation is
a prerequisite for sialylation.
Shifting IgG Fc binding specificity from type I to type II FcRs
can result in significant in vivo responses and precise regulation
of sFc abundance is likely a fundamental homeostatic process.
One known consequence of increasing type II FcR signaling is
anti-inflammatory activity, a classic example of which is the
therapeutic anti-inflammatory activity of high-dose intravenous
immunoglobulin (IVIG) (Anthony et al., 2008a; Kaneko et al.,
2006; Washburn et al., 2015). sFcs in IVIG, acting through bind-
ing of the type II FcR DC-SIGN on innate effector cells, stimulate
IL-33 production resulting in downstream anti-inflammatory
processes (Anthony et al., 2011). Disrupted balance in type I
and type II FcR signaling likely occurs in several inflammatory
diseases such as rheumatoid arthritis and granulomatosis
with polyangiitis in which decreased abundance of sFc are
found on autoantibodies such as anti-citrullinated peptide
(ACPA) and anti-proteinase 3 (PR3) antibodies, respectively.
Sialylation of anti-ACPA and anti-PR3 Fcs is reduced during
disease flares, while disease remission is correlated with
elevated Fc glycan sialylation of those autoantibodies (de
Man et al., 2014; Espy et al., 2011; Scherer et al., 2010;
Tomana et al., 1988; van de Geijn et al., 2009; Wuhrer et al.,
2015).
Just as sialic acid-modified Fc glycans play a critical role
in the regulation of inflammatory processes, the presence
or absence of a branching fucose moiety modulates the
interaction of IgG Fcs with FcgRIIIa to enhance or inhibit
IgG-mediated ADCC and monocyte/macrophage activation
(Uman˜a et al., 1999) (Shinkawa et al., 2003). Afucosylated
Fc domains have increased affinity for the activating receptor
FcgRIIIa that results from a stabilizing interaction between the
N-glycan on FcgRIIIa with the afucosylated Fc glycan (Ferrara
et al., 2011). Removal of fucose from monoclonal therapeutic
antibodies such as rituximab and trastuzumab improved their
clinical efficacy by increasing binding to FcgRIIIa, thereby
enhancing ADCC activity (Dalle et al., 2011; Junttila et al.,
2010). As with sialylated glycoforms, diseases associated
with modulations in fucose levels on Fc glycans suggests
strict regulation of Fc fucosylation; an example of this is fetal
or neonatal alloimmune thrombocytopenia, in which IgG
specific for human platelet antigens (HPA) have significantly
diminished levels of fucosylated Fc glycans, with levels
of afucosylated anti-HPA correlating with disease severity
(Kapur et al., 2014).
Figure 1. Type I and Type II FcR Binding Characteristics of Human
Anti-HA IgG
(A) Overview of Type I and Type II FcR family.
(B) Subclass distribution of pre-vaccination anti-H1 HA (Cal/09) IgG from a
cohort of ten healthy adults. Mean IgG1: 56.18% (SD 14.16), IgG2: 37.64% (SD
15.14), IgG3: 5.37% (SD 3.82). IgG4 levels were below the limit of detection.
(C) Type I FcR binding characteristics of IgG subclasses.
(D) Schematic overview of the Fc-associated glycan structure. Composition of
the core Fc glycan (boxed) can be modified by addition of fucose (F), N-ace-
tylglucosamine (N), galactose (G), and sialic acid (S) residues.
(E) Fc glycoform distribution on baseline anti-H1 HA IgG1 from our patient
cohort.
(F) Effect of Fcglycoformsonbinding to type I and type II FcRs. Fcglycovariants
were categorized into: sialylated (blue; +S [G1FS, G2FS]), afucosylated (red;
F, [G0,G1,G2]) and ‘‘neutral,’’ definedby thepresenceof fucoseandabsence
of sialic acid (with branching GlcNAc in pink; +N, [G0FN, G1FN, G2FN], or
without branching GlcNAc in gray; S, +F [G0F, G1F, G2F]).
Error bars in (B) and (E) indicate SD. See also Figure S1.
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That Fc glycan modulation may result in autocrine B cell
signaling through IC-FcR interactions, potentially directing
the antibody response to vaccination, is suggested by the ob-
servations that Fc glycan composition can change following
vaccination (Selman et al., 2012) and that sFc can bind
CD23, the type II FcR expressed on activated B cells (Sonder-
mann et al., 2013). The present study was designed to deter-
mine whether Fc structure within vaccine antigen-IgG ICs
might be regulated as a mechanism of directing FcR-mediated
processes involved in maturation of antibody responses. Our
approach was to characterize modulations in the structural
determinants of Fc domains (IgG subclass and Fc glycan
composition) on IgGs elicited by administration of the trivalent
influenza virus vaccine (TIV) in healthy subjects. Next, we per-
formed a series of directed experiments to determine what
role, if any, the modulations played in determining vaccine re-
sponses. Our results on the natural regulation of Fc domain
structure during the evolution of protective vaccine responses
suggest immunization strategies involving administration of
ICs containing sFc to elicit broadly protective antibodies
against influenza viruses.
Figure 2. Regulation of Fc Glycan Composi-
tion Following TIV Vaccination
(A–D) Fc glycoforms on anti-H1 HA (Cal/09) IgG1
were analyzed. (A) Sialylated (sFc) and (B) fuco-
sylated (fucFc) glycoforms were significantly
elevated on day 7 post-vaccination. (C) Gal-
actosylation (GalFc) levels were modulated to a
small degree following vaccination. (D) Bisected
GlcNAc (bGlcNAcFc) modifications were not
regulated.
(E and F) Anti-HA (predominantly globular head-
specific) and anti-HA stalk IgG1 differed signifi-
cantly in Fc glycoform profile at week 3, with
sialylated, fucosylated glycan levels highest on
anti-HA IgG1 and lowest on stalk-specific IgG1.
(G) No difference in level of bisecting GlcNAc was
observed. Bold line represents groupmean in each
panel.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
determined by two-tailed, paired Student’s t tests.
See also Figure S2.
RESULTS
Characterization of Fc Domain
Structure on TIV-Elicited IgGs
Healthy adults were vaccinated with the
2012–2013 TIV. Sera were drawn at
baseline (pre-vaccination), day 7, week
3, week 5, and week 7 following vaccina-
tion and antigen-specific IgGs were iso-
lated for subsequent analysis of Fc glycan
composition and IgG subclass (Fig-
ure S1A). At baseline, all subjects were
positive for IgG against the H1 HA vaccine
component, A/California/04/2009 (H1N1
virus), by H1 binding ELISA and the hem-
agglutination inhibition (HAI) test using
homologous virus (Figures S2A and S2B). Baseline anti-H1 IgG
was characterized for subclass distribution and Fc glycan
composition (Figures 1B and 1E). Fc glycoforms on baseline
anti-H1 IgG were predominantly neutral, with an inter-subject
range of 66.3%–88.3%, bisecting GlcNAcmoieties were present
with a range of 6.2%–14.6%, sialylated glycoforms were present
with a range of 4.6%–18.5%, and afucosylated glycans were
present with a range of 4.27%–15.07% (Figure S2C). Anti-H1
IgG at baseline contained significantly more sFc and less fucosy-
lated (fucFc) than total IgG, while subclass distribution was not
different between H1-specific and total IgG (Figures S2D–S2F).
Following vaccination, modulations in the abundance of sFc
glycoforms on H1-specific IgG were observed. sFc glycoforms
were significantly elevated and at peak abundance by day 7
post-vaccination; this was mirrored by an increase in fucFc by
day 7. sFc glycoforms and fucFc on anti-H1 IgG were consis-
tently elevated above pre-vaccination levels through week 7
except for a significant dip at week 3 post-vaccination (Figures
2A and 2B).
Because galactosylation is a prerequisite for sialylation of the
Fc glycan, the presence of galactose could be a limiting factor in
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determining the abundance of sialic acid modifications. Analysis
showed that galactose (GalFc) levels were modulated to a small,
but statistically significant degree following vaccination, but that
the overall abundance of galactosylated glycans was over 90%
at every time point (Figure 2C). This was several fold higher than
sialylated glycans, suggesting that galactosylation was not
limiting and that modulations in sialylation were independently
regulated. There was no apparent regulation of bisected GlcNac
glycoforms (bGlcNAcFc) (Figure 2D).
In addition to regulation of Fc glycoforms over time following
vaccination, analysis of HA-specific IgG from a single time point,
week 3, revealed that specific Fc glycoforms can be linked to
Fab specificity, possibly due to differential glycosylaytion by
distinct IgG-producing B cell subsets such as plasmablasts
(PB) and memory B cells. Anti-HA (predominantly globular
head-specific) and anti-HA stalk IgG differed significantly in Fc
glycoform profile, with sialylated, fucosylated glycan levels high-
est on total anti-HA IgG and lowest on anti-HA stalk IgG (Figures
2E and 2F and Figure S2E). No differences were observed in
levels of bisecting GlcNAc (Figure 2G).
Day 7 post-vaccination was characterized by an increase in
sFc on anti-H1 IgG, which would increase type II FcR binding
by ICs. In contrast, week 3 post-vaccination was characterized
by diminished sFc and elevated afucosylated Fc (afucFc), which
would shift the signaling balance toward activating Type I FcRs
(Figure 3A). This shift in Fc glycoform composition toward acti-
vating type I FcR signaling at week 3 was mirrored by modula-
tions in subclass distribution of anti-H1 IgGs, from a median
IgG1 abundance of 35.2% at baseline, to a median level of
75.18% by week 3 (Figure 3B).
Fc Glycoforms Present Following Vaccination Mirror
Glycosyltransferase Expression in Activated B cell
Subsets
Peak levels of sialylated and fucosylated Fc glycans at day 7
post-vaccination mirrored a peak in plasmablast (PB) abun-
dance in the peripheral blood of our study subjects, in accor-
dance with the well-described kinetics of plasmablast expan-
sion that occurs following TIV administration (Figure S3A)
(Wrammert et al., 2008). In addition, the amount of anti-H1
IgG produced during the early plasmablast response corre-
lated with the change in sFc abundance on anti-HA IgG in
the first 7 days following vaccination (p = 0.0065) (Figure S3B).
These observations led us to hypothesize that sialylated,
fucosylated Fc glycoforms may be produced, at least in
part, by PB. Because the increase in relative abundance of
afucFc and asialylated Fc glycoforms from day 7 to week 3
mirrored a small increase in peripheral memory B cells in our
patient cohort (Figure S3C), as has been previously described
(Pinna et al., 2009), we hypothesized that that those glyco-
forms may derive from memory B cells. Intracellular staining
of PB and memory B cells for the relevant glycosyltrans-
ferases, ST6Gal1 and FUT8, revealed increased ST6Gal1
expression and non-significantly increased FUT8 expression
in PB over memory B cells (Figures S3D and S3E). In addition,
gene analysis of day 7 PB and memory B cells from six pa-
tients who received the 2009–10 TIV revealed elevated levels
of ST6Gal1 (p = 0.06) and FUT8 (p = 0.03) in PB over memory
B cells (Figures S3E and S3G), supporting the possible pro-
duction of sialylated, fucosylated Fc glycans by PB and less
sialylated, less fucosylated Fc glycans by memory cells. Unlike
ST6Gal1 and FUT8, B4GALT1, coding for a galactosyltransfer-
ase involved in Fc glycan modification, was not significantly
elevated in PB (Figure S3H).
Sialylated Fc Abundance Predicts Influenza Virus
Vaccine Efficacy, Defined by Change in HAI+ Titer
Post-Vaccination
To investigate the significance of the regulated changes in
Fc glycan composition following TIV vaccination, we assessed
association of specific Fc glycoform abundance with change
in hemagglutination inhibition titer (HAI), a commonly used
measure of TIV efficacy. In particular, since the degree of HA-
specific plasmablast expansion on day 7 post-vaccination has
been observed to loosely correlate with vaccine response, we
investigated any association between production of sialylated
Figure 3. Modulations in Fc Domain Structure Favor Type II FcR
Binding at Day 7 and Type I FcR Binding at Week 3 Post-Vaccination
(A) Fc glycoforms shift from type II FcR binding (high in sFc) at day 7 to type I
FcR binding (high in afucFc content) by week 3.
(B) The activating FcR binding glycoform profile at week 3 was mirrored by a
peak in IgG1 subclass. IgG4 was not in sufficient abundance to accurately
quantify. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 determined by the
Tukey post hoc test.
See also Figure S3.
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IgG on day 7 and vaccine efficacy as measured by HAI titer by
week 3 (Nakaya et al., 2011; Wrammert et al., 2008). Indeed,
the change in abundance of sialylated glycoforms on anti-HA
IgG in the first week following vaccination was predictive of sub-
sequent increase in HAI activity (Figure 4A). In addition, sialylated
glycoform abundance predicted affinity of anti-HA IgG at week 3
post-vaccination (Figure 4B). These data suggested that the
abundance of sialylated Fc glycoforms produced following TIV
administration could regulate the quality of the overall vaccine
response.
Sialylated Fc Glycoforms in ICs Trigger Upregulation of
FcgRIIB on B Cells in a CD23-Dependent Manner
To determine themechanisms bywhich sFcwithin immune com-
plexesmightmodulate B cell activation, we studied the effects of
sFc ICs onB cells in a variety of in vitro and in vivo assays. Pooled
IgG from week 3 post-vaccination, either with native sFc levels
(17.6% on anti-HA IgG) or neuraminidase treated to remove
native sialic acids (asialylated) (Figure S4) was complexed with
California/04/2009 (Cal/09) H1 HA protein to form sialylated or
asialylated IC (sIC or aIC). These ICs were incubated with human
CD19+ PBMCs and analysis after 24 hr incubation revealed
increased expression of FcgRIIB, the inhibitory type I Fc recep-
tor, on cells incubated with sIC but not aIC or HA protein alone
(Figure 5A). Similarly, a recombinant anti-HA mAb, PY102 (Dinca
et al., 1993), was expressed with sialylated Fc glycoforms
(23.7% sFc), or in an asialylated form, and was mixed with
A/PR8/1934 (PR8) H1 HA protein to form sIC or aIC. These
mAb ICs were then incubated with BJAB cells and, consistent
with the primary B cell assay, incubation with sICs, but not aIC
or HA protein alone induced upregulation of FcgRIIB expression
(Figure 5B).
Next, to determine how sialylated ICs might affect B cells
in vivo, the human post-vaccination IgG/Cal/09 HA ICs (sIC
and aIC) were used to prime mice, followed by HA protein boost
3 weeks later. Ten days post-boost, peripheral B cells were
analyzed for FcgRIIB expression; antigen-specific peripheral B
cells from mice primed with sIC showed increased expression
of FcgRIIB, whereas mice primed with aICs showed no such
elevation (Figure 5C). Similarly, sIC or aIC made from mAb
PY102 and PR8 HA protein were used to vaccinate mice;
3 days post-vaccination, germinal center B cells from mice
immunized with sIC, but not aIC or HA alone had increased
FcgRIIB expression (Figure 5D). Because CD23 is the only type
II FcR expressed on B cells, we next determined whether upre-
gulation of FcgRIIB was dependent on CD23 expression.
CD23-deficient mice did not display upregulation of FcgRIIB
on germinal center B cells, demonstrating that sICs acted
through CD23 to trigger upregulation of B cell FcgRIIB
(Figure 5D).
IgG Elicited by Sialylated ICs Are Higher Affinity for
Antigen
Increased FcgRIIB expression is known to elevate thresholds
for selection of B cells based on affinity of BCR, thus, we
characterized the affinity of anti-HA IgG elicited by immuni-
zation with sICs (Bolland and Ravetch, 2000; Pearse et al.,
1999). The affinity of IgGs elicited by human post-vaccination
IgG/Cal/09 HA ICs was measured using an affinity ELISA
assay that was modified from a nitrophenyl system for eval-
uation of anti-HA IgGs; this assay measures the ratio of high-
affinity to all-affinity binding IgGs (Herzenberg et al., 1980;
Kaisho et al., 1997). The affinity for the Cal/09 HA1 subunit
was also evaluated using a method that measures the quan-
tity of IgG remaining bound following treatment with 7M urea
(Verma et al., 2012). IgGs elicited by the sIC priming protocol
had significantly higher affinity for Cal/09 HA1 (primarily glob-
ular head), the highly conserved stalk domain of the H1 sub-
type HA protein, and for the complete Cal/09 HA glycopro-
tein (Figures 6A–6D). Consistent with the lack of FcgRIIB
upregulation using the sIC priming protocol in CD23-deficient
mice (Figure 5D), elevated affinity of elicited IgGs was not
achieved in CD23-deficient mice (Figure 6D). The affinity of
IgGs elicited by mAb PY102/PR8 HA ICs for the PR8 H1 pro-
tein or the PR8 stalk domain was assessed using surface
plasmon resonance (SPR) analysis (Verma et al., 2012). The
polyclonal serum antibody dissociation off-rate for anti-HA
IgG from mice primed with sIC was found to be approxi-
mately 10- to 20-fold lower than that of IgG from mice
primed with aIC- or CD23-deficient mice that received sIC
(Figure 6E).
Higher Affinity IgGs Mediate Broad Protection against
H1N1 Influenza Viruses
To determine any functional significance associated with
increasing affinity of anti-HA IgGs, we tested pooled IgG from
mice primed with polyclonal, human, post-vaccination IgG/Cal/
09 HA IC or HA alone for protective activity (pools were derived
Figure 4. Sialylated Fc Abundance Predicts
Influenza Virus Vaccine Efficacy
(A) Fold change in sFc on anti-HA IgG1 from
baseline to day 7 post-vaccination (sFc, day7/BL)
predicted fold change in HAI titer from baseline to
week 3 (HAI, week 3/BL).
(B) Spearman’s rank correlation: sFc abundance at
week 3 post-vaccination (% sFc, week 3) predicted
affinity of anti-HA IgG at week 3 (anti-HA affinity,
week 3). Correlation analysis was used to determine
the Pearson correlation coefficient (r) (following
confirmationofnormaldistribution) andSpearman’s
rankcorrelation coefficient (rs), linear regressionwas
used to determine goodness of fit (r2).
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from sera tested in Figure 6). IgG pools had equivalent HAI
endpoint titers using virus expressing the homologous HA
used for vaccination (A/Netherlands/602/2009) (Figure S5A)
and equivalent binding activity for Cal/09 or Cal/09 stalk proteins
(Figures S5B–S5G). For challenge experiments, virus was pre-
incubated with purified IgG prior to intranasal infection; thus,
weight loss was a function of dose of infectious virus remaining
after incubation with IgG pools. On challenge, equivalent protec-
tion was observed against the H1N1 virus A/Netherlands/602/
2009, which expresses the homologous HA used for vaccination
(Figures 7A and 7B). In contrast, when we evaluated only anti-
stalk IgGs for protective activity using a virus that expresses a
chimeric hemagglutininmolecule (cH5/1) comprised of the highly
conserved H1 stalk domain and an irrelevant head subtype
domain (H5), we observed a difference in protective potency of
the IgG pools. Only the higher affinity IgGs elicited by priming
with sIC conferred anti-stalk-mediated protection (Figures 7C
and 7D).
Next, equivalent challenge experiments were performed using
IgG from mice immunized with mAb PY102/PR8 HA IC (sIC in
wild-type mice, sIC in CD23-deficient mice or aIC) or PR8 HA
alone. Purified IgG pools had equivalent binding titers for PR8
HA (Figure S5H). Mice were challenged with A/PR8/1934 virus,
which expresses the homologous H1 HA used for vaccination
and, as before, complete protection was achieved with all IgG
pools (Figures 7E and 7F). In contrast, only IgG elicited by
sIC protected mice from challenge with either A/FM/1/1947
H1N1 virus or A/Netherlands/602/2009 H1N1 virus (Figures
7G–7J), demonstrating breadth of protection conferred by higher
affinity IgG elicited by sIC.
DISCUSSION
That sFc produced during the early plasmablast response was
found to correlate with subsequent production of HAI+ anti-
body suggested a possible requirement for immunomodulatory
type II FcR signaling in the ontogeny of protective TIV re-
sponses. Further experiments demonstrated that sFc within im-
mune complexes triggered upregulation of B cell FcgRIIb, thus
modulating the selection of B cells in favor of those expressing
higher affinity BCR. Our studies suggest a model whereby TIV
vaccination triggers plasmablast expansion and production of
sFc IgG. Immune complexes formed with sFc IgG signal
through the type II FcR CD23 on activated B cells, triggering
increased FcgRIIb expression. This results in an elevation of
threshold for BCR affinity that is required for B cell survival
and, ultimately, production of higher affinity, more potently pro-
tective IgG (Figure S6).
Several studies, including the present, have found that base-
line titer of anti-HA IgG correlates negatively with the magnitude
of TIV response, so that low baseline titer predicts greater vac-
cine response (Figure S7A) (Beyer et al., 1996; Sasaki et al.,
2008; Tsang et al., 2014). Low baseline anti-HA titer also predicts
greater plasmablast frequency (Tsang et al., 2014) and predicted
increased production of sFc glycoforms by day 7 post-vaccina-
tion (Figure S7B). Overall, low baseline anti-HA IgG predicts large
plasmablast expansion and abundant production of sialylated
glycoforms within the week following vaccination, resulting in
a greater change in HAI+ IgG. Of note, greater production of
sialylated Fc glycoforms by day 7 could also be predicted by
baseline sialylated Fc abundance, with lower baseline sialylated
Figure 5. sFc in ICs Trigger Upregulation of
FcgRIIb on B Cells
(A) sIC or aIC were generated from pooled, post-
vaccination human IgG and Cal/09 HA protein.
Human, CD19+ PBMCs were incubated with sIC,
aIC or HA protein alone. FACS analysis following
incubation revealed an increased number of cells
expressing FcgRIIB with sIC but not with aIC or HA
incubation.
(B) sIC or aIC were generated from PY102 and PR8
HA protein. BJAB B cells were incubated with
sIC, aIC or HA at the indicated IC concentrations.
Incubation with sIC but not aIC or HA alone
increased FcgRIIB expression on B cells.
(C) Antigen-specific (HA-specific) peripheral B
cells from mice primed with sIC showed increased
FcgRIIB, whereas mice primed with aICs or naive
mice (NM) showed no elevation in peripheral B cell
FcgRIIB expression. Five mice per group. Data are
represented as mean ± SD.
(D) Splenic B cells in the light and dark zones of the
germinal center frommice primed with sIC, but not
aIC or mock showed increased expression of
FcgRIIB. Increased FcgRIIB expression was not
present in CD23 knockout mice (CD23/) primed
with sIC.
All panels are representative of experiments
performed in duplicate or triplicate. See also
Figure S4.
Cell 162, 160–169, July 2, 2015 ª2015 Elsevier Inc. 165
glycoform abundance correlating with greater subsequent sFc
production (Figure S7C).
The finding that protective anti-stalk IgGs can be elicited by
sialylated ICs is significant as anti-stalk IgGs can mediate broad
protection against antigenically distinct influenza viruses (Kram-
mer et al., 2013; Pica et al., 2012; Wang et al., 2010). One prac-
tical application suggested by the observation that sialylated im-
mune complexes can drive selection of higher affinity B cells,
would be to use this as a strategy to selectively elicit higher affin-
ity anti-stalk IgGs, thereby generating broader and more potent
anti-HA responses. The finding also suggests an affinity require-
ment for protective anti-stalk IgGs that is not present for globular
head-specific antibodies; higher affinity may be required of anti-
stalk IgGs in order to restrict the conformation change in the HA
that occurs at low pH, thus preventing fusion of the viral envelope
with the host cell.
Because balanced FcR signaling is a requirement for genera-
tion of specific immune responses, strict regulation of Fc domain
structure within ICs must occur (Bolland and Ravetch, 2000; Fu-
kuyama et al., 2005). We show that this regulation occurs
through synchronizedmodulations in determinants of Fc domain
structure following exposure to antigen. The changes observed,
over the weeks following vaccination, would regulate type I and
type II FcR signaling within B cell follicles where antigen can be
retained for months and even years following exposure (Nossal,
1992). PB that expand following TIV are a possible source of sFc
IgG observed at day 7, while memory B cells may contribute to
production of the less fucosylated, less sialylated Fc glycoforms
observed at week 3. Production of less fucosylated, less sialy-
lated glycoforms by memory B cells may be supported by the
finding that these glycoforms are present with greater abun-
dance on IgGs specific for the highly conserved stalk domain
of the HA. A shift toward Fc domains with increased type I FcR
binding at week 3 was pronounced in both Fc glycoform and
IgG subclass distribution; a possible function of the increased
activating type I FcR signaling may be to provide an adaptive
mechanism for enhancing phagocyte activity during prolonged
antigen exposure or infection.
Further studies will be required to dissect the undoubtedly
complex role of Fc glycoform modulations during evolution of
humoral immune responses, including both sialylated and low-
fucose forms, as they are likely involved in regulation of multiple
processes within the germinal center in addition to B cell activa-
tion and selection.
EXPERIMENTAL PROCEDURES
Clinical Studies
The 2012–2013 TIV vaccination study was conducted at the Rockefeller Univer-
sity Hospital in New York City in accordance with a protocol approved by the
Institutional Review Board of Rockefeller University (protocol #TWA-0804), in
compliance with guidelines of the International Conference on Harmonization
Good Clinical Practice guidelines, and was registered on www.clinicaltrials.
gov (NCT01967238).Samplesweredrawn from tenhealthy adult volunteers (Fig-
ure S1). B cells analyzed for gene expression derived from six donors as part of a
study approved by the Emory University institutional review board (IRB
#00022916). Healthy volunteers received the 2009–2010 trivalent inactivated
influenza vaccine. All samples were processed within 30 min of being drawn;
sera and PBMCswere stored at80C and were thawed once prior to analysis.
Recombinant Proteins and Generation of Immune Complexes
Recombinant anti-HA mAb PY102 was expressed as a human IgG1 in 293T
cells stably expressing human ST6GAL1 and B4GALT1 and purified using pro-
tein G chromatography as previously described (Bournazos et al., 2014). HA
proteins were expressed in a baculovirus system as previously described
(Pica et al., 2012). ICs were formed by incubation of molar ratio 30:1 (purified,
Figure 6. sFc in ICs Elicit Higher Affinity IgG
(A–E) IgGs elicited by sIC had significantly higher affinity for (A and B) the
globular head, (C) the stalk domain of the HA protein, and (D) the wild-type Cal/
09 H1 subtype HA protein when compared with the affinities of IgG elicited by
aIC or HA alone. Only wild-type mice and not CD23-deficient mice generated
higher affinity, anti-HA IgGs in response to an immunization protocol with sIC
priming. Affinity measurement in (B) was determined by 7M urea ELISA, ex-
pressed as IgG bound to HA following 7M urea treatment/IgG bound without
7M urea treatment; affinity measurements in (A), (C) and (D) were determined
by ELISA, expressed as binding ratio to low density/high density of plate-
bound HA protein. Data are represented as mean ± SEM (E) SPR analysis of
off-rate constant of polyclonal IgG elicited by mAb PY102-HA ICs in wild-type
or CD23/ mice. sIC priming protocol in wild-type mice elicited approxi-
mately 10- to 20-fold higher affinity IgGs over aIC priming or sIC priming in
CD23/ mice.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 determined by two-tailed
Student’s t test.
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polyclonal human IgG) or 3:1 (mAb PY102) IgG:HA trimer for 1 hr at 4C. These
IgG:HA ratios were designed to generate 1:1 complexes with IgG and HA
monomer; a 30:1 ratio was used for polyclonal IgG:HA based on a predicted
anti-HA frequency of 1 in 10 IgGs post-vaccination. IgG subclass and Fc
glycan composition were determined by mass spectrometry; size of ICs was
determined by size exclusion chromatography (See Supplemental Experi-
mental Procedures for detailed protocols).
Fc Glycan Analysis
IgGs were isolated from serum by protein G purification. HA-specific IgGs
were isolated on agarose resin (Pierce) coupled to HA protein. Total anti-H1
HA IgGs were captured on Cal/09-coupled resin while anti-H1 stalk proteins
were captured using resin coupled to a chimeric hemagglutinin protein ex-
pressing the Cal/09 stalk and an H5 subtype globular head domain. IgG Fc-
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Figure 7. Immunization with sIC Elicits IgGs
with Greater Breadth of Protective Potency
against Distinct H1 Influenza Viruses
(A and B) Purified IgGs were pooled from mice
primed with sIC (Cal/09 HA) or Cal/09 HA alone
followed by two boost immunizations of Cal/09 HA.
IgG from either pool conferred equivalent protec-
tion against A/Netherlands/602/2009 (H1N1).
(C and D) In contrast, only IgGs elicited by priming
with sICs conferred anti-stalk-mediated protection
against the chimeric cH5/1 virus that expresses an
HA with an H1 stalk domain and an H5 subtype
globular head.
(E and F) Purified IgGs were pooled from mice
primed with monoclonal PY102-PR8 HA ICs or
PR8 HA alone. ICs used were: sIC in wild-type
mice, sIC in CD23/ mice or aIC in wild-type
mice. IgG from all pools conferred equivalent
protection against A/PR8/1934 virus (H1N1).
(G–J) In contrast, only IgG elicited by sIC protected
mice from challenge with (G and H) A/FM/1/1947
(H1N1) virus or (I and J) A/Netherlands/602/2009
virus.
The number of animals used was 5–10 per group in
each experiment. See also Figure S5.
associated glycans were analyzed by mass spec-
trometry following tryptic digestion of purified IgG
or on-bead IgG. Relative IgG subclass distribution
was determined by mass spectrometric quantifi-
cation of subclass-specific tryptic peptides. IgG4
was not in sufficient abundance to accurately
quantify. See Supplemental Experimental Proce-
dures for detailed mass spectrometric methods.
ELISAs
HAELISAswere performed as described previously
(Wang et al., 2010). Negative control (naive mouse
serum or binding values of human IgGs on the irrel-
evant protein BSA) values were subtracted from
readings given by test samples. Study subjects
were determined to have positive IgG binding titers
when binding was five times above background.
For affinity ELISAs, sera diluted 1:200 were incu-
bated on plates coated with 1ug/ml HA protein
(low density) or 6 mg/ml HA (high density). The affin-
ity of HA-specific IgG was expressed as a ratio of
binding to low-density:high-density HA-coated
plates. This method was adapted from the well-es-
tablishedassay used formeasurement of polyclonal
anti-nitrophenyl-hapten affinity (Herzenberg et al.,
1980). The 7M urea affinity ELISA was performed as previously described
(Verma et al., 2012). HA1 protein (Sino Biological), chimeric cH5/1 protein
(head domain derived fromH5N1 strain A/Viet Nam/1203/04 and a stalk domain
derived from H1N1 strain A/Puerto Rico/8/34) or Cal/09 or PR8 full-length HA
proteins were used.
Hemagglutination Inhibition Assay
Sera were tested in a standard hemagglutination inhibition assay, as previ-
ously described (WHO, 2002).
Surface Plasmon Resonance Analysis
The binding properties of serum antibodies were analyzed by SPR (Biacore
T-200. GE Healthcare). Protein G-purified serum IgG from vaccinated mice
was immobilized to the surface of a CM5 sensor chip (GE Healthcare) using
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amine coupling chemistry at a density of 1,000 RU. Varying concentration
(1 nM–50 nM) of either PR8-HA or cH5/1 HA were injected sequentially over
flowcells of the sensor chip. Samples were fit to heterogeneous ligand binding
model and the off-rate constant (kd/s) was calculated.
In Vitro Studies
Human, CD19+ PBMCs or BJAB cells were treated with IL-4 (200 ng/ml) and
CD40L (5 mg/ml) to increase surface expression of CD23 prior to incubation
with IC.
In Vivo Studies
All mice were maintained in a specific-pathogen–free facility at the Rockefeller
University and all studies were approved by the Rockefeller University Institu-
tional Animal Care and Use Committee.
Polyclonal IC immunization: For mouse immunizations using human serum-
derived ICs, A/California/04/2009 HA protein (10 mg) was delivered alone, or in
complex with pooled, protein G-purified, week 3 post-vaccination IgG from
vaccinated subjects. As control, asialylated IgG was prepared by treatment
of IgG with a2-3,6,8 Neuraminidase (New England Biolabs) as described (An-
thony et al., 2011). Mice previously administered ICs or HA in PBS were
boosted, intraperitoneally, at 3 week intervals, with 10 mg HA in adjuvant (com-
plete/incomplete Freund’s or Alum).
For in vivo neutralization studies, anesthetized mice (female C57BL/6J; 6- to
8-week-old) were infected intranasally with 5 mLD50 of the A/Netherlands/
602/09 (H1N1) or cH5/1PR8N1PR8 virus (the HA contains a head domain derived
from H5N1 strain A/Viet Nam/1203/04 and a stalk domain derived from H1N1
strain A/Puerto Rico/8/34—generated as described in Hai et al., 2012). IgGs
from vaccinated mice were purified from pooled sera using protein G (GE
Healthcare) and mixed with virus prior to intranasal infections. For the
Netherlands/09 challenge, 10 mg/ml IgG was mixed with virus, for the cH5/1
challenge, 200 mg/ml IgG was used. Mouse body weight was recorded daily,
and death was determined by a 20% body weight loss threshold.
Monoclonal IC immunizations: For PY102 mAb immunizations, 20 mg PR8
HA and 50 mg PY102 or 20 mg PR8 HA alone was delivered intravenously to
6-week-old wild-type or CD23/ BALB/c mice. Boosts were administered
as described above. For challenge studies, mice were anesthetized and in-
fected as described above. A mixture of mouse-adapted virus (A/PR8/1934
(H1N1), A/FM/1/1947 (H1N1) or A/Netherlands/602/09 (H1N1) and purified
polyclonal IgG (75 mg/ml) from vaccinated mice was pre-incubated at room
temperature for 30 min. Six- to eight-week old female BALB/c mice were
then infected with 5 mLD50 of virus. Mice were weighed daily to monitor
morbidity and animals that exceeded 25% weight loss were euthanized.
Statistical Analysis
All data were analyzed in Prism 6 (GraphPad). Results from multiple experi-
ments are presented as mean ± SEM. Correlation analysis was used to deter-
mine the Pearson correlation coefficient, r. Linear regression was used to
determine goodness of fit, R2.
Two tail paired/unpaired Student’s t tests or ANOVA followed by Tukey post
hoc analysis were performed to assess differences in themean values of quan-
titative variables. Non parametric tests of significance were performed if
normal distribution could not be assessed or if populations were not normally
distributed.
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